




## N<sup>6</sup>-Propargyl-ATP (N<sup>6</sup>pATP)

N<sup>6</sup>-Propargyl-adenosine-5'-triphosphate, Sodium salt

| Cat. No.     | Amount |
|--------------|--------|
| CLK-NU-001-1 | 1 mg   |
| CLK-NU-001-5 | 5 mg   |



Structural formula of N<sup>6</sup>-Propargyl-ATP (N<sup>6</sup>pATP)

### For research use only!

**Shipping:** shipped on blue ice

**Storage Conditions:** store at -20 °C

Short term exposure (up to 1 week cumulative) to ambient temperature possible.

**Shelf Life:** 12 months after date of delivery

**Molecular Formula:** C<sub>13</sub>H<sub>18</sub>N<sub>5</sub>O<sub>13</sub>P<sub>3</sub> (free acid)

**Molecular Weight:** 545.23 g/mol (free acid)

**Exact Mass:** 545.01 g/mol (free acid)

**Purity:** ≥ 95 % (HPLC)

**Form:** white to off-white solid

**Solubility:** 10 mM Tris-HCl pH 7.5

**Spectroscopic Properties:** λ<sub>max</sub> 262 nm, ε 18.0 L mmol<sup>-1</sup> cm<sup>-1</sup> (Tris-HCl pH 7.5)

### Applications:

*in vitro* AMPylation of proteins<sup>[1,2]</sup>

*in vitro* polyadenylation of RNA<sup>[3]</sup>

The resulting alkyne-functionalized protein<sup>[1,2]</sup> or RNA<sup>[3]</sup> can subsequently be processed via Cu(I)-catalyzed (azide-alkyne) click chemistry that offers the choice

- to introduce a Biotin group for subsequent purification tasks (via Azides of Biotin)
- to introduce fluorescent group for subsequent microscopic imaging (via Azides of fluorescent dyes)
- to crosslink the RNA to azide-functionalized biomolecules e.g. proteins

Presolski *et al.*<sup>[4]</sup> and Hong *et al.*<sup>[5]</sup> provide a general protocol for Cu(I)-catalyzed click chemistry reactions that may be used as a starting point for the set up and optimization of individual assays.

Agonistic ligand, mainly for nucleoside receptor A<sub>1</sub>  
Nucleoside-triphosphates can be converted by different membrane-bound phosphatases into nucleosides acting as nucleoside receptor ligands. In some cases nucleoside phosphates act also directly on nucleoside receptors.

**Please note:** This compound contains a phosphoramidate linkage which is hydrolyzed at pH <7.0.  
For preparation of a 10 mM solution use 100 mM buffer (for example: bicarbonate, borate, phosphate and Tris) to prevent degradation at acidic pH.

### Related Products:

Copper (II)-Sulphate (CuSO<sub>4</sub>), #CLK-MI004

Tris(3-hydroxypropyl)triazolylmethylamine (THPTA), #CLK-1010

Sodium Ascorbate (Na-Ascorbate), #CLK-MI005

### Selected References:

[1] Grammel *et al.* (2011) A Chemical Reporter for Protein AMPylation. *J. Am. Chem. Soc.* **133**:17103.

[2] Broncel *et al.* (2012) A New Chemical Handle for Protein AMPylation at the Host-Pathogen Interface. *ChemBioChem* **13**:183.

[3] Grammel *et al.* (2012) Chemical Reporter for Monitoring RNA Synthesis and Poly (A) Tail Dynamics. *ChemBioChem* **13**:1112.

[4] Presolski *et al.* (2011) Copper-Catalyzed Azide-Alkyne Click Chemistry for Bioconjugation. *Current Protocols in Chemical Biology* **3**:153.

[5] Hong *et al.* (2011) Analysis and Optimization of Copper-Catalyzed Azide-Alkyne Cycloaddition for Bioconjugation. *Angew. Chem. Int. Ed.* **48**:9879.

Sirci *et al.* (2012) Ligand-, structure- and pharmacophore-based molecular fingerprints: a case study on adenosine A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub>, and A<sub>3</sub> receptor



## N<sup>6</sup>-Propargyl-ATP (N<sup>6</sup>pATP)

N<sup>6</sup>-Propargyl-adenosine-5'-triphosphate, Sodium salt

antagonists. *J. Comput. Aided Mol. Des.* **26**:1247.

Volonte *et al.* (2009) Membrane components and purinergic signalling: the purinome, a complex interplay among ligands, degrading enzymes, receptors and transporters. *FEBS J.* **276**:318.

Yegutkin (2008) Nucleotide and nucleoside converting enzymes: Important modulators of purinergic signalling cascade. *Biochim. Biophys. Acta* **1783**:673.

Joshi *et al.* (2005) Purine derivatives as ligands for A3 adenosine receptors. *Current Topics in Medicinal Chemistry* **5**:1275.

Volpini *et al.* (2002) N6-Alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists of the human adenosine A3 receptor and starting point for searching A2B ligands. *J. Med. Chem.* **45 (15)**:3271.

Hess (2001) Recent advantages in adenosine receptor antagonist research. *Expert Opin. Ther. Patents* **11 (10)**:1533.

Jacobson (2001) Probing adenosine and P2 receptors: design of novel purines and nonpurines as selective ligands. *Drug Development Res.* **52**:178.

Jacobson *et al.* (2001) Ribose modified nucleosides and nucleotides as ligands for purine receptors. *Nucleosides, Nucleotides & Nucleic Acids* **20 (4)**:333.

Van Galen *et al.* (1994) A binding site model and structure-activity relationships for rat A3 adenosine receptor. *Molecular Pharmacology* **45**:1101.